title: Characterization of antihypertensive activity of ABBOTT-81988, a nonpeptide angiotensin II antagonist in the renal hypertensive rat.
abstract: 2-(N-Propyl-N[(2'-[1H-tetrazol-5-yl]biphenyl-4yl)methyl]amin o) pyridine-3-carboxylic acid (ABBOTT-81988), a novel nonpeptide angiotensin II (AII) antagonist, was evaluated to characterize its antihypertensive activity in the conscious renal hypertensive rat. Oral or i.v. administration of ABBOTT-81988 at 0.03 to 0.3 mg/kg produced a dose-dependent, sustained decrease in mean arterial pressure (MAP; control 162-173 mm Hg, n = 27) of approximately 20 to 70 mm Hg. At a dose of 0.3 mg/kg p.o., ABBOTT-81988 lowered MAP to a normotensive level for more than 24 hr and did not change heart rate. During its antihypertensive effect (delta MAP, -28% approximately -35%), ABBOTT-81988 (0.1-03 mg/kg i.v.) decreased total peripheral resistance (delta resistance, -31% approximately -43%), and cardiac output remained either unchanged or slightly elevated. ABBOTT-81988 (0.3 mg/kg i.v.) produced an additional antihypertensive effect (delta MAP, -12 +/- 2%, n = 5) in captopril-pretreated (10 mg/kg i.v.) hypertensive rats, but captopril (10 mg/kg i.v.) had no effect in ABBOTT-81988-pretreated (0.3 mg/kg i.v.) rats. In the normotensive rat, ABBOTT-81988 (0.3 mg/kg p.o.) had no effect on basal MAP, but it inhibited the AII-induced (0.1 microgram/kg i.v.) pressor response by 51% to 91% for 24 hr, whereas the responses to norepinephrine (0.3 microgram/kg i.v.), vasopressin (0.03 IU/kg i.v.) and bradykinin (3 micrograms/kg i.v.) were not affected. It is concluded that ABBOTT-81988 is a safe and efficacious AII antagonist that may have use in the treatment of human hypertension.
authors.affiliation: Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois.
authors.forename: J Y
authors.initials: JY
authors.lastname: Lee
authors.forename: S A
authors.initials: SA
authors.lastname: Buckner
authors.forename: M E
authors.initials: ME
authors.lastname: Brune
authors.forename: R B
authors.initials: RB
authors.lastname: Warner
authors.forename: M
authors.initials: M
authors.lastname: Winn
authors.forename: B
authors.initials: B
authors.lastname: De
authors.forename: T M
authors.initials: TM
authors.lastname: Zydowsky
authors.forename: T J
authors.initials: TJ
authors.lastname: Opgenorth
authors.forename: D J
authors.initials: DJ
authors.lastname: Kerkman
authors.forename: J F
authors.initials: JF
authors.lastname: Debernardis
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001920:Bradykinin / Q000494:pharmacology; D004562:Electrocardiography / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006977:Hypertension, Renal / Q000188:drug therapy*; D008297:Male; D009539:Nicotinic Acids / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology
chemical_list: D000959:Antihypertensive Agents; D009539:Nicotinic Acids; D013777:Tetrazoles; D014667:Vasopressins; D000804:Angiotensin II; C081174:A 81988; D001920:Bradykinin; D009638:Norepinephrine